News about "Biocon"

Biocon's Pegfilgrastim Biosimilar Gets Japan MHLW Approval

Biocon’s pegfilgrastim biosimilar receives Japan MHLW marketing approval, strengthening the company’s biosimilar portfolio and expanding access in Japan.

Biocon | 25/08/2026 | By News Bureau

Biocon Announces US Commercial Launch of Yesafili, a Biosimilar to Regeneron's Eylea 2 mg

Biocon has launched Yesafili, an interchangeable biosimilar to Eylea 2 mg in the US, expanding access to treatment for Age-related Macular Degeneration (AMD) and other retinal diseases.

Biocon | 03/08/2026 | By News Bureau

Biocon Receives Health Canada Approval for Yesintek Autoinjector Pen

Biocon has received Health Canada approval for the Yesintek autoinjector pen to treat plaque psoriasis, psoriatic arthritis, Crohn's Disease (CD) and Ulcerative Colitis (UC).

Biocon | 29/07/2026 | By News Bureau

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili

Biocon has published pivotal clinical data supporting the effectiveness of Yesafili, its Food and Drug Administration (FDA)-approved interchangeable aflibercept biosimilar, demonstrating comparable safety, efficacy, and immunogenicity.

Biocon | 09/07/2026 | By News Bureau |  132

Biocon Expands Diabetes Care in Malaysia as Duopharma Wins Insulin Tenders

Biocon strengthens diabetes care in Malaysia as Duopharma Biotech secures insulin tenders worth over MYR 225 million for human insulin, insulin glargine, and insulin aspart.

Biocon | 26/06/2026 | By News Bureau |  126

Biocon Launches Bosaya and Aukelso Denosumab Biosimilars in US

Biocon launches Bosaya and Aukelso denosumab biosimilars in the US following FDA approval with interchangeable status, expanding treatment options for osteoporosis and bone metastasis patients.

Biocon | 08/04/2026 | By News Bureau |  144

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Biocon | 08/12/2025 | By Dineshwori |  149

Biocon Clarifies Media Reports on Possible Biocon Biologics Merger

Biocon has issued a clarification regarding recent media reports suggesting that the company is considering a potential merger of its unlisted subsidiary, Biocon Biologics Ltd. (BBL), along with IPO and share swap options.

Biocon | 14/11/2025 | By Dineshwori |  410

Biocon Posts Robust Q2FY26 Results as Biosimilars and Generics Drive Double-Digit Growth

Biocon reported a robust financial performance for the second quarter of FY26, with total revenue rising 21 percent year-on-year (YoY) to INR 4,389 crore, compared to INR 3,623 crore in Q2 FY25.

Biocon | 12/11/2025 | By Dineshwori |  474

Biocon's Cranbury Facility in US Passes FDA Inspection, Supports Expansion Plans

Biocon’s inspection concluded with a single observation, which the company will address within the stipulated timeframe, and it is not expected to impact ongoing business operations

Biocon | 15/10/2025 | By Dineshwori |  297